Hyo S. Han

5.0k citations

146 papers · 2.5k indexed · 1 hit paper · h-index 28

Impact in

Biological Psychiatry top 2%
- Tryptophan and brain disorders
Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- CAR-T cell therapy research

Papers in

Oncology 118
- HER2/EGFR in Cancer Research 36
- Cancer Treatment and Pharmacology 29
- Cancer Immunotherapy and Biomarkers 18
- Lung Cancer Research Studies 17
- PARP inhibition in cancer therapy 16
Biological Psychiatry 8

Co-authors: Ricardo Costa William J. Gradishar Hatem Soliman Roohi Ismail‐Khan Daniel M. Sullivan Scott Antonia Brian J. Czerniecki Nicholas N. Vahanian
Journals: Journal of Clinical Oncology (39 papers)Cancer Research (26 papers)Breast Cancer Research and Treatment (8 papers)Annals of Oncology (7 papers)Clinical Cancer Research (4 papers)
Partner nations: United States France Canada

In The Last Decade

Hyo S. Han

134 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review 2018 · 337 citations

Peers

Countries citing papers authored by Hyo S. Han

Since Specialization

Citations

This map shows the geographic impact of Hyo S. Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyo S. Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyo S. Han more than expected).

Fields of papers citing papers by Hyo S. Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hyo S. Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyo S. Han. The network helps show where Hyo S. Han may publish in the future.

Co-authors

The 25 scholars most cited alongside Hyo S. Han, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hyo S. Han Line = papers co-authored together Hyo S. Han links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort Cancer Research ·Erika Hamilton, Rinath Jeselsohn, Sara A. Hurvitz, Dejan Juric, Hyo S. Han, Melinda L. Telli, George Zahrah, Rita Nanda, Yuanyuan Zhang, Weiwei Tan, Elizabeth K. Duperret, Eric Zhi, Cecile Mather, Anne F. Schott	2024	2
2	Abstract PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) Cancer Research ·Sara Hurvitz, Fabrice André, Massimo Cristofanilli, Giuseppe Curigliano, Antonio Giordano, Hyo S. Han, Miguel Martín, Barbara Pistilli, Hope S. Rugo, Robert Wesolowski, Igor Gorbatchevsky, Sibylle Loibl	2024	1
3	Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer JAMA Oncology ·Hyo S. Han, Amy L. Aldrich, Saurabh Garg, R. Jared Weinfurtner, Jonathan V. Nguyen, Qianxing Mo, Junmin Whiting, Jennifer Childress, Hatem Soliman, Ricardo Costa, Avan Armaghani, Aixa Soyano, John V. Kiluk, Susan Hoover, Marie Catherine Lee, Nazanin Khakpour, Nithin Shenoi, Zena Jameel, Gary K. Koski, Brian J. Czerniecki	2024	1
4	Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease JAMA Oncology ·Kamran A. Ahmed, Priya Kumthekar, Yolanda Piña, Youngchul Kim, Michael A. Vogelbaum, Hyo S. Han, Peter Forsyth	2024	2
5	204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients ESMO Open ·Hope S. Rugo, Robert Wesolowski, Erica Stringer-Reasor, Hyo S. Han, Jennifer M. Specht, Claire Dees, Peter Kabos, Ulka N. Vaishampayan, Seth A. Wander, Janice Lu, Keerthi Gogineni, Alexander I. Spira, Anne F. Schott, Maysa Abu‐Khalaf, Sarah C. Mutka, Samuel Suzuki, Igor Gorbatchevsky, Rachel M. Layman	2023	1
6	Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial Nature Medicine ·Hatem Soliman, Deanna Hogue, Hyo S. Han, Blaise Mooney, Ricardo Costa, Marie Catherine Lee, Bethany L. Niell, Angela Williams, Alec Chau, Shannon Falcon, Aixa Soyano, Avan Armaghani, Nazanin Khakpour, R. Jared Weinfurtner, Susan Hoover, John V. Kiluk, Christine Laronga, Marilin Rosa, Hung T. Khong, Brian J. Czerniecki	2023	50
7	390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial Annals of Oncology ·Erika Hamilton, Hyo S. Han, Anne F. Schott, Antoinette R. Tan, Rita Nanda, Dejan Juric, N. Hunter, Pamela N. Münster, Bruno Fang, G. Zahrah, J. Ranciato, Richard Gedrich, Eric Zhi, Y. Zhang, Weiwei Tan, C. Mather, Jessica M. Perkins, Sibyl Anderson, Sara A. Hurvitz	2023	12
8	Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development Molecular Aspects of Medicine ·Namrata Gautam, Ganesan Ramamoorthi, Nicholas Champion, Hyo S. Han, Brian J. Czerniecki	2023	9
9	Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial. Journal of Clinical Oncology ·Hyo S. Han, Ricardo Costa, Avan Armaghani, Susan Hoover, John V. Kiluk, Marie Catherine Lee, Hatem Soliman, Hung T. Khong, Loretta Loftus, Qianxing Mo, Jennifer A. Childress, Edith Abraham, Kaitlin Hendrix, Amy L. Aldrich, Marina Sehovic, Zena Jameel, Shannon Falcon, R. Jared Weinfurtner, Aixa Elena Soyano Muller, Brian J. Czerniecki	2023	1
10	Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study Clinical Cancer Research ·Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Jie Xiao, Jessica A. Sorrentino, Janet K. Horton, Joyce O’Shaughnessy	2021	28
11	Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia Cancer Medicine ·James Sun, Xiaojun Zhong, Junjie Ma, Weihong Sun, Hyo S. Han, Hatem Soliman, Loretta Loftus, Ricardo Costa, Avan Armaghani, Aixa E. Soyano‐Muller, Brian J. Czerniecki, M. Catherine Lee, John V. Kiluk, Nazanin Khakpour, Susan Hoover, Christine Laronga, Hung T. Khong	2021	13
12	Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial Annals of Oncology ·Hyo S. Han, Banu Arun, Bella Kaufman, Hans Wildiers, Michael Friedländer, Jean-Pierre Ayoub, Shannon L. Puhalla, Bruce Allen Bach, Madan G. Kundu, Nikhil Khandelwal, Feng Dai, Sudipta Bhattacharya, David Maag, Christine K. Ratajczak, Véronique Dièras	2021	26
13	Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes JCO Oncology Practice ·Jinani Jayasekera, Susan T. Vadaparampil, Susan Eggly, Richard L. Street, Tanina Foster Moore, Claudine Isaacs, Hyo S. Han, Bianca Augusto, Jennifer García, Katherine Lopez, Suzanne C. O’Neill	2020	11
14	Clinical Outcomes of Breast Cancer Patients with HER2-positive Brain Metastases Treated with Stereotactic Radiation and Trastuzumab Emtansine International Journal of Radiation OncologyBiologyPhysics ·M.N. Mills, Chelsea Walker, Chetna Thawani, Afrin Naz, Nicholas Figura, Mingwei Yu, Theodore Robinson, Arnold B. Etame, J.K. Liu, Michael A. Vogelbaum, Peter Forsyth, Hany Soliman, Hyo S. Han, K.A. Ahmed	2020	2
15	<p>Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data</p> Breast Cancer Targets and Therapy ·Avan Armaghani, Hyo S. Han	2020	16
16	A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures Contemporary Clinical Trials ·Heather Jim, Aasha I. Hoogland, Hyo S. Han, Eva Culakova, Charles E. Heckler, Michelle C. Janelsins, Geoffrey C. Williams, Julienne E. Bower, Stephen Cole, Zeruesenay Desta, Margarita Bobonis Babilonia, Gary R. Morrow, Luke J. Peppone	2020	8
17	A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2<sup>+</sup> breast cancer Drug Design Development and Therapy ·Ricardo Costa, Saif Zaman, Susan C. Sharpe, Irene Helenowski, Colleen Shaw, Hyo S. Han, Hatem Soliman, Brian J. Czerniecki	2019	14
18	Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy Breast Cancer Research and Treatment ·Barbara Pistilli, Timothy Pluard, Ander Urruticoechea, Daniele Farci, Anthony Kong, Thomas Bachelot, Stephen Chan, Hyo S. Han, G. Jerusalem, Patrick Urban, Douglas Robinson, Sylvie Le Mouhaër, Emmanuelle di Tomaso, Cristian Massacesi, Cristina Saura	2017	50
19	Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer Clinical Breast Cancer ·Hyo S. Han, Anthony M. Magliocco	2016	16
20	Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma Breast Cancer Research and Treatment ·Eleni Andreopoulou, Ivette Vigoda, Vicente Valero, Dawn L. Hershman, George Raptis, Linda T. Vahdat, Hyo S. Han, James R. Wright, Christine Pellegrino, Massimo Cristofanilli, Ricardo H. Álvarez, Karen Fehn, Susan Fineberg, Joseph A. Sparano	2013	15

About Hyo S. Han

Hyo S. Han is a scholar working on Oncology, Biological Psychiatry, Pulmonary and Respiratory Medicine, Genetics and Cancer Research, having authored 146 papers that have together received 2.5k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (48 papers), HER2/EGFR in Cancer Research (36 papers), Cancer Treatment and Pharmacology (29 papers), Brain Metastases and Treatment (22 papers), Cancer Immunotherapy and Biomarkers (18 papers), Lung Cancer Research Studies (17 papers), PARP inhibition in cancer therapy (16 papers) and Monoclonal and Polyclonal Antibodies Research (15 papers). The work is most often cited by research in Biological Psychiatry (205 citations), Oncology (1.4k citations), Pulmonary and Respiratory Medicine (810 citations), Cancer Research (339 citations) and Genetics (218 citations). Hyo S. Han has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Ricardo Costa, William J. Gradishar, Hatem Soliman, Roohi Ismail‐Khan, Daniel M. Sullivan, Scott Antonia, Brian J. Czerniecki, Nicholas N. Vahanian, Maricer P. Escalón and Izidore S. Lossos. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer Research and Treatment, Annals of Oncology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact